Covid-19 roundup: Daiichi's mRNA shot enters the clinic; South Africa sells its AstraZeneca supply to neighbors
Another mRNA-based vaccine is entering the clinic.
Over a year after Moderna kicked off trials for their mRNA-based Covid-19 shot, Japanese drugmaker Daiichi-Sankyo announced that they have moved their own such candidates into trials. Like most early studies, the 152-person Phase I/II trial will measure how safe the jab is and how well it induces neutralizing antibodies against the virus.
The Daichi candidate joins a broader second tier of mRNA vaccines now making their way through clinical trials. Those are led by EU-backed and Novartis-partnered CureVac, which is looking to provide pivotal data later this year, and the Sanofi-Translate Bio partnership, which kicked off clinical trials earlier this month.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.